Dr. Thomas VERMEULIN

Médecin DIM

Année d’arrivée au Centre

2019

Parcours professionnel

  • Médecin DIM, responsable du service PMSI & facturation – Groupe Mathilde Médical Développement – Rouen
  • Assistant Hospitalo-Universitaire – CHU et UFR Médecine & Pharmacie – Rouen
  • Assistant Spécialiste Recherche Régional – CHU de Rouen et unité Inserm 1086 Anticipe à Caen
  • Interne en Santé Publique et Médecine Sociale – CHU – Rouen

Formation

  • Docteur en Médecine, qualification en Santé Publique et Médecine Sociale – UFR Médecine & Pharmacie – Rouen
  • Master 2 en Expertise Economique des Questions de Santé – Université Paris-Dauphine – Paris
  • Master 2 en Management des Organisations Sanitaires et Médico-Sociales – UFR Médecine & Pharmacie et IAE – Rouen –
  • Master 1 en Sciences Médicales et Pharmaceutiques – UFR Médecine & Pharmacie – Rouen

Interventions pratiquées ou expertise

  • Information médicale
  • Économie de la santé

Sociétés savantes

  • Président du Collège Régional d’Information Médicale entre 2018 et 2020.

Publications majeures

  • Comparison of real costs in the French healthcare system in newly diagnosed pemphigus patients: first-line treatment with rituximab versus standard corticosteroid regimen. Data of a national multicentre trial. Br J Dermatol. https://doi.org/10.1111/bjd.18563
  • The impact of a patient’s social status on the cost of vaginal deliveries: an observational study in a French university hospital. J. Gynecol. Obstet. Hum. Reprod. 48, 33–38. https://doi.org/10.1016/j.jogoh.2018.10.020
  • Totally implanted venous access-associated adverse events in oncology: Results from a prospective 1-year surveillance programme. Bull. Cancer (Paris) 105, 1003–1011. https://doi.org/10.1016/j.bulcan.2018.09.005
  • Response to “Identification of appropriate and potentially avoidable emergency department referrals in a tertiary cancer care center” by Duflos et al. Support. Care Cancer Off. J. Multinatl. Assoc. Support. Care Cancer. https://doi.org/10.1007/s00520-017-3939-6
  • Conformité du délai d’initiation de la chimiothérapie adjuvante pour cancer du côlon : élaboration d’un indicateur qualité à partir du PMSI. Oncologie 20, 85–91. https://doi.org/10.3166/onco-2018-0014
  • French study group on autoimmune bullous skin diseases (2017). First-line rituximab combined with short-term prednisone versus prednisone alone for the treatment of pemphigus (Ritux 3): a prospective, multicentre, parallel-group, open-label randomised trial. Lancet Lond. Engl. https://doi.org/10.1016/S0140-6736(17)30070-3
  • Copy Number Variations in DCC/18q and ERBB2/17q are Associated with Disease-Free Survival in Microsatellite Stable Colon Cancer. Int. J. Cancer. https://doi.org/10.1002/ijc.30584
  • Incidence of postoperative nosocomial endophthalmitis: results of an 8-year prospective surveillance program in a university hospital in France. J. Hosp. Infect. https://doi.org/10.1016/j.jhin.2017.05.008
  • Pediatric-Like Acute Lymphoblastic Leukemia Therapy in Adults With Lymphoblastic Lymphoma: The GRAALL-LYSA LL03 Study. J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol. 34, 572–580. https://doi.org/10.1200/JCO.2015.61.5385
  • Is the Risk of Wound Infection Related to Bilateral Internal Thoracic Artery Graft Potentiated by Age? Ann. Thorac. Surg. 102, 1239–1244. https://doi.org/10.1016/j.athoracsur.2016.03.068